Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 14/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8207926 | 0.90 | TRPV1 (0.51) | CACNA1HHDAC1HDAC6GPR119 | |
| SCHEMBL8224778 | 0.90 | GPR119 (0.52) | CACNA1HCYP3A4CYP3A5HDAC1HDAC6 | |
| SCHEMBL14263432 | 0.87 | CACNA1H (0.54) | CACNA1HMEN1KMT2AGPR119 | |
| SCHEMBL8217831 | 0.85 | HDAC1 (0.53) | MEN1KMT2AHDAC1HDAC6GPR119 | |
| SCHEMBL8205482 | 0.85 | CACNA1H (0.55) | CACNA1H | |
| SCHEMBL8218916 | 0.85 | CACNA1H (0.57) | CACNA1H | |
| SCHEMBL8209853 | 0.83 | TRPV1 (0.55) | CACNA1HNPSR1GPR119 | |
| SCHEMBL8210218 | 0.83 | CACNA1H (0.46) | CACNA1HMEN1KMT2ANPSR1 | |
| SCHEMBL8217839 | 0.83 | CACNA1H (0.49) | CACNA1HMEN1KMT2A | |
| SCHEMBL8210646 | 0.83 | GPR119 (0.52) | CACNA1HGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | CACNA1H 2829/4885CYP3A4 119/4885CYP3A5 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.